NRG Oncology/RTOG 0415 试验中前列腺癌大分割放疗后晚期不良事件的耐受剂量
基于多中心 NRG Oncology/RTOG 0415 低危前列腺癌试验中大分割放疗组 521 例患者,中位随访 5.9 年,晚期≥2 级胃肠道和泌尿生殖毒性粗发生率分别为 19% 和 29%。研究通过剂量-体积建模提出晚期胃肠道毒性的候选预测因子,并量化了限制直肠小体积高剂量热点对降低胃肠道毒性的作用。
要点
- 大分割放疗组 70 Gy/2.5 Gy 分次,晚期≥2 级胃肠道毒性 19%、泌尿生殖毒性 29%。
- 直肠最热 5% 体积最小剂量(D5%[Gy])和直肠绝对体积<35 Gy 是晚期胃肠道毒性候选预测因子。
- 将晚期胃肠道毒性从 20% 降至 10% 需将 D5%[Gy] 从≤65 Gy 降至≤62 Gy。
核心结论
- 低危前列腺癌中度大分割放疗后,晚期胃肠道毒性随直肠小体积接受更高剂量而增加。
- 本工作提供定量证据表明,在此类大分割放疗方案的临床实践中限制直肠小体积剂量热点,可能进一步降低相关胃肠道毒性发生率。
研究设计与样本
- 多中心 NRG Oncology/RTOG 0415 低危前列腺癌试验中大分割放疗组 521 例。
- 大分割放疗组方案为 70 Gy、2.5 Gy/分次,采用三维适形放疗/调强放疗(N=108/413)。
- 中位随访 5.9 年,将完整大分割放疗队列随机分为训练集和验证集(70% 和 30%),并保持毒性率。
- 在训练集中基于剂量-体积切点(EQD2Gy;膀胱/直肠 α/β=6 Gy/3 Gy)、年龄、急性≥2 级毒性和治疗技术,采用单因素和多因素逻辑回归结合自举法建模。
- 候选预测因子在 p≤0.05 确定,所选多因素模型在验证集中探索,以验证集受试者工作特征曲线下面积(AUCvalidation)在 AUCtraining±标准差内且 p≤0.05、Hosmer-Lemeshow p 值(pHL)>0.05 判断模型可推广性。
主要发现
- 晚期≥2 级胃肠道和泌尿生殖毒性粗发生率分别为 19% 和 29%。
- 晚期胃肠道毒性有三个候选预测因子:直肠最热 5% 体积的最小剂量(D5%[Gy])、直肠绝对体积<35 Gy 和急性胃肠道毒性(AUC=0.59-0.63;p=0.02-0.04)。
- 两个可推广的多因素模型,即 D5%[Gy] 联合或不联合急性胃肠道毒性(AUCvalidation=0.64、0.65;p=0.01、0.03;pHL=0.45-0.56)。
- 将晚期胃肠道毒性从 20% 降至 10% 需将 D5%[Gy] 从≤65 Gy 降至≤62 Gy(逻辑函数参数:17+(0.24D5%[Gy]))。
- 急性泌尿生殖毒性仅显示预测晚期泌尿生殖毒性的趋势(AUCtraining=0.57;p=0.07)。
关键数值与推荐
- 晚期胃肠道毒性候选预测因子:直肠最热 5% 体积的最小剂量(D5%[Gy])、直肠绝对体积<35 Gy、急性胃肠道毒性(AUC=0.59-0.63;p=0.02-0.04)。
- 可推广多因素模型:D5%[Gy] 联合或不联合急性胃肠道毒性(AUCvalidation=0.64、0.65;p=0.01、0.03;pHL=0.45-0.56)。
- 将晚期胃肠道毒性从 20% 降至 10% 需将 D5%[Gy] 从≤65 Gy 降至≤62 Gy。
临床怎么用
- 作者认为,在此类大分割放疗方案的临床实践中限制直肠小体积剂量热点,可能进一步降低相关胃肠道毒性发生率。
局限性
- 急性泌尿生殖毒性仅显示预测晚期泌尿生殖毒性的趋势(AUCtraining=0.57;p=0.07)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE: Hypofractionated radiotherapy (HRT) regimens for prostate cancer are emerging, but tolerance doses for late adverse events are scarce. The purpose of this study is to define dose-volume predictors for late gastrointestinal and genitourinary (GI and GU) toxicities after HRT in the multi-center NRG Oncology/RTOG 0415 low-risk prostate cancer trial (N = 521). MATERIAL/METHODS: Treatment in the studied HRT arm was delivered as 70 Gy at 2.5 Gy/fraction with 3D-CRT/IMRT (N = 108/413). At a median follow-up of 5.9 years, the crude late ≥Grade 2 GI and GU toxicities were 19% and 29%, respectively. For modeling, the complete HRT cohort was randomly split into training and validation (70% and 30%; preserved toxicity rates). Within training, dose-response modeling was based on dose-volume cut-points (EQD2Gy; bladder/rectum: α/β = 6 Gy/3Gy), age, acute ≥Grade 2 toxicity, and treatment technique using univariate and multivariate logistic regression on bootstrapping (UVA and MVA). Candidate predictors were determined at p ≤ 0.05, and the selected MVA models were explored on validation where model generalizability was judged if the area under the receiver-operating curve in validation (AUCvalidation) was within AUCtraining ± SD with p ≤ 0.05, and with an Hosmer-Lemeshow p-value (pHL) > 0.05. RESULTS: Three candidate predictors were suggested for late GI toxicity: the minimum dose to the hottest 5% rectal volume (D5%[Gy]), the absolute rectal volume <35 Gy, and acute GI toxicity (AUC = 0.59-0.63; p = 0.02-0.04). The two generalizable MVA models, i.e., D5%[Gy] with or without acute GI toxicity (AUCvalidation = 0.64, 0.65; p = 0.01, 0.03; pHL = 0.45-0.56), suggest that reducing late GI toxicity from 20% to 10% would require reducing D5%[Gy] from ≤65 Gy to ≤62 Gy (logistic function argument: 17+(0.24D5%[Gy])). Acute GU toxicity showed only a trend to predict late GU toxicity (AUCtraining = 0.57; p = 0.07). CONCLUSION: Late GI toxicity, following moderate HRT for low-risk prostate cancer, increases with higher doses to small rectal volumes. This work provides quantitative evidence that limiting small rectal dose 'hotspots' in clinical practice of such HRT regimens is likely to further reduce the associated rates of GI toxicity.
引用
- Thor M, Deasy JO, Paulus R, et al. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiother Oncol. 2019. PMID: 31015166. doi:10.1016/j.radonc.2019.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。